Aligos Therapeutics, Inc.
ALGS
$10.17
$0.303.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -98.81% | -136.82% | 152.45% | -326.55% | -480.54% |
| Total Depreciation and Amortization | -15.06% | 33.51% | -71.09% | 170.56% | -3.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 755.42% | 98.62% | -195.10% | 2,933.75% | 107.23% |
| Change in Net Operating Assets | 64.73% | 124.25% | -883.33% | 87.74% | -177.40% |
| Cash from Operations | -57.02% | 25.85% | -13.62% | 8.45% | -3.12% |
| Capital Expenditure | -77.06% | -153.49% | -53.57% | -7.69% | -271.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 221.78% | 10.70% | -320.12% | 91.86% | -73.94% |
| Cash from Investing | 220.96% | 10.54% | -320.64% | 92.08% | -74.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -900.00% | -- | -- | -760.00% | 68.75% |
| Issuance of Common Stock | -- | -- | 72,572.86% | 13,900.00% | -99.66% |
| Repurchase of Common Stock | 75.57% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 70.06% | -100.17% | 104,788.66% | 2,525.00% | -101.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.26% | -249.87% | 2,106.84% | 117.16% | -146.71% |